Swiss drugmaker Roche has won U.S. antitrust approval for its US$4.3 billion deal to buy gene therapy specialist Spark Therapeutics , the Federal Trade Commission said on Monday, clearing the way for the Swiss drugmaker’s push into treating rare diseases including hemophilia A.
